BioCentury
ARTICLE | Clinical News

HIV/AIDS vaccine: Additional Phase IIa data

November 18, 2013 8:00 AM UTC

GeoVax reported additional data from the double-blind, placebo-controlled, U.S. and Peruvian Phase IIa HVTN 205 trial in 299 healthy, uninfected volunteers showing that HIV gp140 IgG antibody titers in patients who received the company's HIV-1 DNA vaccine as a primer followed by the HIV-1 MVA vaccine as a booster declined by less than 3-fold at 6 months after the last vaccination. GeoVax said the data indicate significant durability of the antibody response. Subjects received the HIV-1 DNA vaccine as a primer given at months 0 and 2 followed by the HIV-1 MVA vaccine as a booster given at months 4 and 6; 3 injections with the MVA vaccine given at months 0, 2 and 6 without the DNA vaccine; or placebo. Data were presented at the AIDS Vaccine meeting in Barcelona. ...